Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Recursion Pharmaceuticals has a consensus recommendation of "Hold" from analysts, with one sell rating, three hold ratings, and two buy ratings; the average 1-year price target is $7.25.
• The company reported a net loss of ($0.41) per share for the most recent quarter, which was below analyst expectations, despite a substantial year-over-year revenue increase of 33.3%.
• Insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals at an average price of $5.52, reducing their ownership by 5.19%.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $7.25.

A number of equities research analysts have recently commented on the stock. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Saturday, September 27th.

Insiders Place Their Bets

In related news, insider Najat Khan sold 36,599 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the sale, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. The trade was a 5.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 8.43% of the company's stock.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Clear Creek Financial Management LLC lifted its stake in Recursion Pharmaceuticals by 9.8% in the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after acquiring an additional 1,907 shares during the period. GAMMA Investing LLC increased its holdings in Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after buying an additional 2,026 shares during the period. TD Waterhouse Canada Inc. increased its holdings in Recursion Pharmaceuticals by 64.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company's stock worth $29,000 after buying an additional 2,200 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Recursion Pharmaceuticals by 16.8% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company's stock worth $78,000 after buying an additional 2,219 shares during the period. Finally, QRG Capital Management Inc. boosted its position in Recursion Pharmaceuticals by 8.5% in the 1st quarter. QRG Capital Management Inc. now owns 28,515 shares of the company's stock worth $151,000 after purchasing an additional 2,244 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Down 0.5%

NASDAQ RXRX traded down $0.03 during trading on Friday, hitting $5.49. 48,861,846 shares of the company's stock traded hands, compared to its average volume of 31,387,524. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The stock has a fifty day moving average of $5.10 and a two-hundred day moving average of $5.15. The firm has a market cap of $2.38 billion, a P/E ratio of -3.08 and a beta of 0.91. Recursion Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The company had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same period in the previous year, the company earned ($0.40) earnings per share. Recursion Pharmaceuticals's quarterly revenue was up 33.3% on a year-over-year basis. As a group, sell-side analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.